Table 1 Demographic and clinical data
Participant Characteristics | AKI-SP1 (N = 267) | AKI-SP2 (N = 154) | p-value |
|---|---|---|---|
Baseline Demographics | |||
Age (year) | 57 ± 18 | 56 ± 17 | 0.84 |
Male (%) | 164 (61) | 104 (68) | 0.19 |
Body Mass Index (kg/m2) | 29 ± 8 | 29 ± 8 | 0.97 |
Race (%) | |||
 Caucasian | 267 (100) | 154 (100) | 1.00 |
Co-Morbidities | |||
 Diabetes Mellitus | 72 (27) | 40 (26) | 0.69 |
 Cirrhosis | 6 (2) | 14 (9) | < 0.01 |
ICU Eventsa | |||
 APACHE III Scores | 74 ± 24 | 111 ± 26 | < 0.01 |
 Sepsis – 3 | 178 (67) | 132 (86) | < 0.01 |
 Vasopressors | 113 (42) | 124 (81) | < 0.01 |
 24 h urine output (ml) | 1680 (1140–2665) | 1199 (563–2050) | < 0.01 |
ICU Laboratory Valuesa | |||
 Maximum White Blood Cell Count (10*9) | 16 ± 8 | 17 ± 13 | 0.25 |
 Low Hematocrit (%) | 30 ± 6 | 31 ± 6 | 0.74 |
 Low Sodium (mEq/L) | 137 ± 6 | 135 ± 5 | < 0.01 |
 Low Albumin (g/dL) | 2.4 ± 0.6 | 2.2 ± 0.7 | < 0.01 |
 Low Platelets (109/L) | 184 ± 101 | 85 ± 75 | < 0.01 |
 Low Sodium Bicarbonate (mEq/L) | 22 ± 5 | 17 ± 5 | < 0.01 |
Biomarker Concentrations (pg/ml) | |||
 Angiopoietin-2 | 23,458 (12,208-38,707) | 74,972 (48,294-128,421) | < 0.01 |
 Angiopoietin-1 | 2361 (1090-5102) | 778 (398–1998) | < 0.01 |
 Soluble Tumor Necrosis Factor Receptor-1 | 10,581 (6828-15,742) | 25,815 (16,084-36,211) | < 0.01 |
Outcomes | |||
 Length of ICU stay, d | 7.5 ± 7.3 | 8.3 ± 8.7 | < 0.01 |
 Maximum 7 day Serum Creatinine (mg/dL) | 1.6 (1.2–2.3) | 2.7 (1.8–4.3) | < 0.01 |
 28-day mortality | 36 (14) | 57 (37) | < 0.01 |